Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Phase of Trial: Phase IV
Latest Information Update: 20 Aug 2014
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ReNew
- Sponsors Merck KGaA
- 12 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Aug 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov record.
- 20 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.